[(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methanol | 858665-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: [(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methanol
• CAS: 858665-29-9
• 化学式: C₂₀H₂₀F₃NO₂
• 分子量: 363.38
• InChiKey: DZPPOXFXOSHCBM-PDWMJMLSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methanol 生成 [(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl methanesulfonate
  参考文献：
  名称：

  Bioorg. Med. Chem. Lett. 2010, 20, 1491-1495

  摘要：

  DOI：
• 作为产物：
  描述：

  [(4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methanol 生成 [(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methanol
  参考文献：
  名称：

  Bioorg. Med. Chem. Lett. 2010, 20, 1491-1495

  摘要：

  DOI：

文献信息

• Substituted Tetrahydroquinolines
  申请人：Schiemann Kai

  公开号：US20080194615A1

  公开（公告）日：2008-08-14

  Disclosed are compounds of formula (I), wherein W, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 have the meanings indicated in claim 1 . Said compounds can be used for the treatment of tumors, among other things.

  本发明揭示了式(I)的化合物，其中W、R、R1、R2、R3、R4、R5、R6和R7具有权利要求书中所示的含义。该化合物可用于肿瘤治疗等方面。
• The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5
  作者：Kai Schiemann、Dirk Finsinger、Frank Zenke、Christiane Amendt、Thorsten Knöchel、David Bruge、Hans-Peter Buchstaller、Ulrich Emde、Wolfgang Stähle、Soheila Anzali

  DOI：10.1016/j.bmcl.2010.01.110

  日期：2010.3

  Here we describe the discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 originally found during a high-throughput screening (HTS) campaign sampling our in-house compound collection. The compounds optimized subsequently and characterized herein were potently inhibiting the ATPase activity of Kinesin-5 and also exhibited consistent cellular activity, in that cells arrested in mitosis and apoptosis induction could be observed. X-ray crystallographic data demonstrated that these inhibitors bind in an allosteric pocket of Kinesin-5 distant from the nucleotide and microtubule binding sites. The selected clinical candidate EMD 534085 caused strong growth inhibition in human tumor xenograft models using Colo 205 colon carcinoma cells at doses below 30 mg/kg administered twice weekly without showing severe toxicity as determined by loss of body weight. (C) 2010 Elsevier Ltd. All rights reserved.
• 2-(Hetero)-aryl substituted tetrahydrochinoline
  申请人：Schiemann Kai

  公开号：US20070203167A1

  公开（公告）日：2007-08-30

  Compounds of the formula I, in which W, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the meanings indicated in Claim 1 , can be employed, inter alia, for the treatment of tumours
• POLYMORPHIC FORMS AND PROCESS
  申请人：Schiemann Kai

  公开号：US20090176820A1

  公开（公告）日：2009-07-09

  The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I wherein R 1 , R 2 , R 3 , R 6 , R 7 and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer.
• US7868172B2
  申请人：——

  公开号：US7868172B2

  公开（公告）日：2011-01-11